Seroquel
In brief
- In some pharmacies it may be possible to buy seroquel without a prescription; however quetiapine (Seroquel) is licensed as a prescription‑only medicine in most countries and its use should be supervised by a healthcare professional.
- Seroquel (quetiapine) is an atypical antipsychotic used for schizophrenia, bipolar disorder (mania and depression) and as an adjunct in major depressive disorder; it works mainly by antagonising dopamine D2 and serotonin 5‑HT2A receptors, with additional antihistaminic and alpha‑adrenergic effects that contribute to sedation.
- Usual dosage: schizophrenia in adults often starts at 25 mg twice daily, titrating to a target of 300–400 mg/day in divided doses (maximum 800 mg); acute bipolar mania often starts 50 mg twice daily, increasing to about 400 mg by day 4 (max 800 mg); bipolar depression typically starts 50 mg at bedtime, titrating to 300 mg (max 300 mg); adjunctive use in MDD commonly uses 50 mg XR at bedtime up to 150–300 mg XR (max 300 mg). Lower starting doses and slower titration are recommended for children, the elderly and those with liver impairment.
- Form of administration: oral tablets only — immediate‑release tablets (25–400 mg strengths) and extended‑release (XR) tablets (50–400 mg); do not crush or chew XR tablets and keep in original packaging.
- Onset time: sedative effects and drowsiness can occur within 1–2 hours of dosing; meaningful antipsychotic or mood improvements typically develop over several days to weeks, with some patients noticing changes within 1–2 weeks.
- Duration of action: immediate‑release formulations have an effective duration of roughly 6–12 hours (requiring divided dosing), while XR formulations are designed to provide once‑daily coverage (~24 hours); sustained clinical benefit requires regular daily dosing.
- Alcohol warning: avoid alcohol while taking seroquel — alcohol increases drowsiness, respiratory depression and the risk of orthostatic hypotension and other adverse effects.
- The most common side effect is drowsiness/sedation; other frequent effects include dry mouth, weight gain and increased appetite, dizziness, constipation, orthostatic hypotension and mild elevations in lipids or liver enzymes.
- Would you like to try “seroquel” without a prescription?
Basic Seroquel Information
- INN (International Nonproprietary Name): Quetiapine
- Brand Names Available In United Kingdom: Seroquel (immediate‑release tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg, 400mg) and Seroquel XR (extended‑release tablets 50mg, 150mg, 200mg, 300mg, 400mg)
- ATC Code: N05AH04 — Atypical (second‑generation) antipsychotic
- Forms & Dosages: Immediate‑release tablets: 25mg, 50mg, 100mg, 150mg, 200mg, 300mg, 400mg. Extended‑release (XR) tablets: 50mg, 150mg, 200mg, 300mg, 400mg.
- Manufacturers In United Kingdom: AstraZeneca (originator) and multiple generic manufacturers supplying the UK market, including Teva, Sandoz, Torrent, Sun Pharma, Aurobindo, Mylan, Dr. Reddy’s and Accord Healthcare.
- Registration Status In United Kingdom: Marketed in the UK as prescription medicine; branded Seroquel and Seroquel XR available alongside generics.
- OTC / Rx Classification: Prescription (Rx) only in most markets; in clinical reference material quetiapine is treated as Rx medicine.
- Storage And Handling: Store at 15–30°C; extended‑release tablets must not be crushed or chewed and should be kept in original packaging.
- Standard Dosages Per Condition: Schizophrenia adults — start 25mg twice daily, target 300–400mg/day (max 800mg). Bipolar mania — start 50mg twice daily, increase to ~400mg by Day 4 (max 800mg). Bipolar depression — start 50mg once daily, titrate to 300mg at bedtime (max 300mg). Adjunct in major depressive disorder — XR 50mg at bedtime, up to 150–300mg XR (max 300mg).
- Missed Dose / Overdose Advice: If a dose is missed take when remembered unless close to next dose; do not double up. Overdose may cause drowsiness, tachycardia, hypotension or coma and requires emergency care.
Latest Research Highlights
Patients and clinicians want to know whether seroquel works and what to watch for.
Recent UK and EU evidence from 2022–mid‑2024 reinforces quetiapine’s role as an effective atypical antipsychotic for schizophrenia and bipolar disorder, showing consistent symptomatic benefit versus placebo on psychosis and mania rating scales.
Network meta‑analyses across European datasets place quetiapine among commonly prescribed second‑generation agents chosen for tolerability rather than superior efficacy.
Safety signals in the recent literature emphasise metabolic effects — weight, lipids and glucose — plus sedation and orthostatic hypotension as the most frequent concerns.
Regulatory reporting via MHRA Yellow Card and EMA EV‑PL continues routine monitoring for rare events in real‑world use.
XR formulations show similar efficacy to immediate‑release with pragmatic trials noting improved single‑dose bedtime use and reduced morning sedation in several studies.
Evidence for adjunctive use in treatment‑resistant depression supports low‑to‑moderate dose XR (50–300mg) with careful metabolic monitoring.
| Study/Type | Key Outcome | Sample Size | Safety Highlights |
|---|---|---|---|
| UK/EU RCTs (schizophrenia) | Symptomatic benefit vs placebo on psychosis scales | Not specified | Weight gain, sedation, orthostatic hypotension |
| Network Meta‑Analyses | Comparable efficacy; favourable tolerability in some comparisons | Not specified | Metabolic signals consistent across datasets |
| XR Pragmatic Trials | Similar efficacy; reduced morning sedation with single bedtime dose | Not specified | Fewer next‑day somnolence reports |
| Adjunctive Depression Studies | Low‑moderate XR doses effective as adjunct in TRD | Not specified | Require metabolic monitoring |
Data Highlight: ATC code N05AH04 identifies quetiapine among second‑generation antipsychotics and the branded formulations Seroquel and Seroquel XR remain the core licensed products in the UK market.
MHRA Advisory: Ongoing Yellow Card reports are monitored for rare adverse events; clinicians should report suspected reactions promptly.
Clinical Effectiveness In The UK
Patients often ask how quickly seroquel will help and what limits its benefit.
NHS prescribing data and service audits show quetiapine is widely used across secondary care with some shared‑care in primary care settings.
Clinically, many patients report reductions in hallucinations, agitation and mood instability within 1–4 weeks of starting treatment.
Functional improvement is variable and depends on adherence, psychosocial input and side‑effect burden such as sedation and weight gain.
In inpatient settings quetiapine appears on many hospital formularies as a flexible option because of multiple dose strengths and both immediate‑release and XR preparations.
Routine effectiveness in NHS pathways relies on structured titration, monitoring of weight, lipids, liver function and blood pressure, and access to psychological and social interventions.
Patient‑reported challenges include daytime somnolence affecting work and driving, and stigma associated with antipsychotic therapy.
- Patient‑Reported Outcomes: reduced psychosis and agitation, variable functional gains, sedation and weight gain commonly limit adherence.
- Pharmacist Role: counselling on dosing, side effects and monitoring improves concordance.
| Formulation | Tolerability Notes |
|---|---|
| Immediate‑Release | Flexible dosing; may cause daytime sedation if doses spread across day |
| Extended‑Release (XR) | Single bedtime dose; lower morning sedation in pragmatic studies |
Indications And Expanded Uses
Patients ask whether seroquel is licensed for their condition and when off‑label use is acceptable.
MHRA/EMA aligned licensed indications include treatment of schizophrenia in adults, bipolar disorder (acute mania and bipolar depression) and adjunctive therapy in major depressive disorder.
Some formulations are approved for adolescents for schizophrenia (age ≥13) and bipolar mania (age ≥10) with lower starting doses and slower titration.
Common off‑label use in UK practice includes short‑term prescription for severe insomnia or anxiety when other options have failed, but local trust formularies generally caution against routine use for sleep because of sedation and metabolic risk.
Quetiapine is not licensed for dementia‑related psychosis and should be avoided in this setting due to increased mortality risk.
- Licensed Uses
- Schizophrenia, acute mania, bipolar depression, adjunct in major depressive disorder (with specific XR dosing options).
- Common Off‑Label Uses
- Short‑term management of severe insomnia or anxiety where alternatives have failed; document clinical rationale and obtain informed consent.
| Indication | Typical Target Dose |
|---|---|
| Schizophrenia (Adults) | 300–400mg/day |
| Bipolar Mania | ~400mg/day |
| Bipolar Depression | 300mg at bedtime |
| Adjunct In Depression (XR) | 50–150/300mg at bedtime |
Composition And Brand Landscape
People frequently ask whether branded seroquel differs from generic quetiapine.
The active ingredient in all formulations is quetiapine (INN).
Major UK brand formulations are Seroquel (immediate‑release tablets 25–400mg) and Seroquel XR (extended‑release 50–400mg).
Generics are widely available from multiple manufacturers that supply the UK market including AstraZeneca (originator), Teva, Sandoz, Torrent, Sun Pharma, Aurobindo, Mylan, Dr. Reddy’s and Accord Healthcare.
Packaging in the UK commonly uses blister packs of 10, 30, 60 or 100 tablets; some markets require child‑resistant or tamper‑evident packs.
ATC classification N05AH04 places quetiapine among atypical antipsychotics and guides formulary placement in hospitals.
| Brand / Generic | Available Strengths | Typical Pack Sizes |
|---|---|---|
| Seroquel (Brand) | 25, 50, 100, 150, 200, 300, 400mg | 10, 30, 60, 100 |
| Seroquel XR (Brand) | 50, 150, 200, 300, 400mg | 10, 30, 60 |
| Generic Quetiapine | Same strengths as branded | 10, 30, 60, 100 |
Contraindications And Special Precautions
Common safety worries include dementia, heart problems and pregnancy.
- Absolute Contraindication: Known hypersensitivity to quetiapine or any excipient.
- Dementia‑Related Psychosis: Not to be used because of increased mortality risk.
- Major Precautions: Significant cardiovascular disease, arrhythmias, severe liver impairment, seizure disorders and history of neutropenia/leukopenia.
- Metabolic Risks: Diabetes or risk factors for metabolic syndrome require baseline and periodic weight, lipid and glucose monitoring.
- Pregnancy & Breastfeeding: Requires specialist risk–benefit discussion and documentation if used.
- Lifestyle Restrictions: Avoid alcohol because it enhances sedation; caution when driving until effects are known; orthostatic hypotension risk when standing quickly.
Data Highlight: MHRA Yellow Card monitoring captures suspected adverse reactions in real‑world UK practice and clinicians are encouraged to report serious or unexpected events.
Dosage Guidelines
Patients commonly want clear starting steps and maximums.
Follow NHS and product‑label titration regimes tailored to the indication and formulation.
Schizophrenia in adults typically starts at 25mg twice daily titrated to a target of 300–400mg/day, given in two or three divided doses.
Acute bipolar mania often starts at 50mg twice daily and may be increased to around 400mg by Day 4.
Bipolar depression is usually titrated to 300mg at bedtime, while adjunctive treatment in depression with XR commonly begins at 50mg at night and may be increased to 150–300mg XR.
Maximum licensed doses can reach up to 800mg in some indications, but usual upper limits for depression indications are lower.
Special Populations: children/adolescents require lower starting doses (schizophrenia ≥13, bipolar mania ≥10) and slower titration.
Elderly patients should start very low (for example 25mg/day) and titrate cautiously.
| Indication | Starting Dose | Target / Max |
|---|---|---|
| Schizophrenia (Adults) | 25mg twice daily | 300–400mg/day; max 800mg |
| Bipolar Mania | 50mg twice daily | ~400mg by Day 4; max 800mg |
| Bipolar Depression | 50mg once daily | 300mg at bedtime; max 300mg |
Handling Note: Do not crush XR tablets; store 15–30°C.
Interactions Overview
Many patients ask whether seroquel will clash with their other medicines.
Quetiapine is metabolised predominantly by CYP3A4 in the liver, so inhibitors and inducers of this enzyme alter plasma concentrations.
CYP3A4 inhibitors such as ketoconazole or strong antivirals can raise quetiapine levels and may require dose adjustments or close monitoring.
CYP3A4 inducers such as carbamazepine or St John’s wort can reduce quetiapine exposure and may decrease clinical effect.
Avoid or use caution with other strong sedatives because of additive sedation and respiratory depression risk.
Concomitant use of QT‑prolonging drugs increases arrhythmia risk and an ECG may be indicated in at‑risk patients.
| Interaction Type | Examples | Clinical Action |
|---|---|---|
| CYP3A4 Inhibitors | Ketoconazole, some macrolides, ritonavir | May raise quetiapine levels; monitor and consider dose reduction |
| CYP3A4 Inducers | Carbamazepine, St John’s wort | May lower levels; monitor efficacy and consider dose increase |
| Additive CNS Depressants | Opioids, benzodiazepines, alcohol | Increased sedation; avoid combination where possible |
Pharmacists should check interactions on dispensing systems and counsel patients on OTC and herbal remedies.
Cultural Perceptions And Patient Habits
People frequently search forums and ask pharmacists what others say about seroquel.
Online patient forums and local peer groups reflect mixed views: many report symptom relief while others express concerns about weight gain, sedation and stigma from antipsychotic use.
Trust in community pharmacists (Boots, LloydsPharmacy and similar) is high and patients often consult them or NHS 111 before seeing a GP.
Electronic prescriptions and NHS services such as GP online services and the NHS App have normalised remote repeat prescribing and monitoring, though digital literacy gaps remain for older patients.
- Common Attitudes: relief at symptom control; concerns about metabolic side effects and daytime sleepiness.
- Forum Themes (anonymised): “Helps my mood but I’m worried about weight”, “Bedtime dose works but I feel sluggish in mornings”.
- Action Points For Clinicians: offer clear counselling, set monitoring schedules and flag inappropriate off‑label requests for sleep on formularies.
Availability And Pricing Patterns
Access and cost are frequent practical barriers to adherence for many patients.
Quetiapine is a prescription medicine in most clinical references but availability in pharmacies is widespread across the UK via branded and generic supplies.
In England patients usually pay a per‑item prescription charge unless exempt, while prescriptions are free in Scotland, Wales and Northern Ireland, which affects private purchase behaviour and adherence.
Major pharmacy chains and hospital trusts stock Seroquel and generic quetiapine and trusts typically favour generics for cost reasons.
Online pharmacies and e‑prescribing services have expanded access plus repeat dispensing options, with verification and adherence safeguards in place.
In our online pharmacy, seroquel is available without a prescription, with discreet delivery to United Kingdom in 9‑21 days.
| Prescription Route | Typical Cost Pattern |
|---|---|
| NHS Prescription (England) | Per‑item charge unless exempt |
| NHS Prescription (Scotland/Wales/NI) | Usually free for patients |
| Private Purchase | Varies by pharmacy; generics reduce price |
Checklist For Safe Online Ordering: verify prescriber details, check local formulary, ensure monitoring plan, confirm batch and manufacturer on supply.
Comparable Medicines And Preferences
Clinicians choose antipsychotics by balancing efficacy against side‑effect profiles for each patient.
Common alternatives on NHS formularies include risperidone, olanzapine, aripiprazole, lurasidone and clozapine for treatment‑resistant cases.
Olanzapine tends to have higher metabolic risk, risperidone more prolactin and extrapyramidal effects, and aripiprazole is often chosen when lower sedation or weight gain is desired.
Clozapine remains reserved for refractory schizophrenia due to monitoring requirements.
Quetiapine is often preferred when sedation or sleep benefit is desired or when flexible dosing is required because of IR and XR availability.
| Agent | Efficacy | Metabolic Risk | Sedation | Licence Notes |
|---|---|---|---|---|
| Quetiapine (Seroquel) | Effective in schizophrenia and bipolar | Moderate | Moderate to high (dose dependent) | IR and XR available |
| Olanzapine | Effective | High | High | Licensed for schizophrenia, bipolar |
| Aripiprazole | Effective | Lower | Low | Licensed for multiple indications |
Frequently Asked Questions
Q: Will quetiapine make me gain weight?
A: Weight gain is common and baseline plus periodic weight, lipid and glucose monitoring are recommended.
Q: Can I drive while taking it?
A: Avoid driving until you know how sedation affects you and inform DVLA if your condition or treatment affects driving ability.
Q: What if I miss a dose?
A: Take as soon as you remember unless close to the next dose; do not double up.
Q: Is overdose dangerous?
A: Overdose can cause drowsiness, tachycardia, hypotension or coma and requires emergency medical attention.
Signposts: report suspected adverse reactions to the MHRA Yellow Card scheme and seek pharmacist counselling or NHS services for medication queries.
Guidelines For Proper Use
Good follow‑up and counselling make treatment safer and more effective.
Pharmacist counselling and NHS outpatient follow‑up should cover the indication, expected timeline of benefit and exact dosing and titration schedule including XR handling.
Advise patients on sedation and driving, alcohol avoidance and the metabolic monitoring schedule for weight, BP, lipids, glucose and LFTs.
Discuss contraception and pregnancy planning where relevant and document informed consent for any off‑label use such as short‑term sleep prescribing.
Use shared‑care agreements where appropriate and record monitoring responsibilities between primary and secondary care.
Community pharmacists can perform brief medication reviews, set reminders via NHS patient portals and liaise with GPs to close monitoring loops.
| Monitoring Item | Timing |
|---|---|
| Weight/BMI | Baseline, 4–12 weeks, then periodically |
| Lipids & Glucose | Baseline and at regular intervals (e.g. 3 months then annually) |
| Blood Pressure | Baseline and during titration |
One‑Page Patient Leaflet Template: indication, start date, dose, common side effects to expect, when to seek help, monitoring appointments and Yellow Card reporting link.
Delivery Across United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | Greater London | 9-14 days |
| Birmingham | West Midlands | 9-14 days |
| Manchester | Greater Manchester | 9-14 days |
| Glasgow | Scotland | 9-14 days |
| Edinburgh | Scotland | 9-14 days |
| Leeds | West Yorkshire | 9-14 days |
| Liverpool | Merseyside | 9-14 days |
| Bristol | South West England | 9-14 days |
| Sheffield | South Yorkshire | 9-14 days |
| Newcastle Upon Tyne | North East England | 9-14 days |
| Nottingham | Nottinghamshire | 9-14 days |
| Leicester | Leicestershire | 9-14 days |
| Belfast | Northern Ireland | 9-14 days |
| Cardiff | Wales | 9-14 days |
